Trial record 1 of 1 for:    NCT01088048
Previous Study | Return to List | Next Study

Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

This study is currently recruiting participants.
Verified March 2014 by Gilead Sciences
Sponsor:
Information provided by (Responsible Party):
Gilead Sciences
ClinicalTrials.gov Identifier:
NCT01088048
First received: March 12, 2010
Last updated: March 27, 2014
Last verified: March 2014
  Purpose

The purpose of this study is to evaluate the safety and clinical activity of idelalisib in combination with CD20 mAb chemotherapeutic agents, Immunomodulatory Agents, mTOR inhibitors and proteasome inhibitor in participants with hematologic malignancies.


Condition Intervention Phase
Indolent Non-Hodgkin's Lymphoma
Chronic Lymphocytic Leukemia
Mantle Cell Lymphoma
Drug: Idelalisib
Drug: Rituximab
Drug: Bendamustine
Drug: Ofatumumab
Drug: Fludarabine
Drug: Everolimus
Drug: Bortezomib
Drug: Chlorambucil
Drug: Lenalidomide
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I Study to Investigate the Safety and Clinical Activity of Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti‑CD20 mAb in Subjects With Relapsed or Refractory Indolent B‑Cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Resource links provided by NLM:


Further study details as provided by Gilead Sciences:

Primary Outcome Measures:
  • Safety of Idelalisib in combination with CD20 mAb and chemotherapeutic agents, mTOR inhibitors, proteasome inhibitors, and/or immunomodulatory agents in participants with hematologic malignancies [ Time Frame: One year ] [ Designated as safety issue: No ]
    Safety will be assessed by collection of adverse events, vital signs, clinical laboratory tests, and ECGs.


Secondary Outcome Measures:
  • Clinical Response Rate [ Time Frame: Every 2-3 months ] [ Designated as safety issue: No ]
    Clinical activity will be evaluated by clinical response rate, assessed by CT scan, clinical laboratory tests, and bone marrow biopsy if indicated.

  • Plasma concentrations of idelalisib [ Time Frame: Every two weeks then as required per protocol ] [ Designated as safety issue: No ]
  • Plasma concentrations of chemotherapeutic agents in a select subset of participants [ Time Frame: Every two weeks then as required per protocol ] [ Designated as safety issue: No ]
  • To investigate the pharmacodynamic effects of idelalisib treatment - assessed by comparing predose and postdose blood samples [ Time Frame: Every two weeks then as required per protocol ] [ Designated as safety issue: No ]

Estimated Enrollment: 224
Study Start Date: April 2010
Estimated Study Completion Date: June 2016
Estimated Primary Completion Date: June 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Idelalisib + Rituximab
Idelalisib 100 mg or 150 mg twice daily plus treatment with rituximab 375 mg/m2 for 8 weekly doses
Drug: Idelalisib
100 mg or 150 mg administered orally twice daily
Other Names:
  • GS-1101
  • CAL-101
Drug: Rituximab
375 mg/m2 administered intravenously
Other Name: Rituxan
Experimental: Idelalisib + Rituximab + Bendamustine
Idelalisib 150 mg twice daily plus rituximab 375 mg/m2 on Day 1 and bendamustine 90 mg/m2 on Days 1 & 2 of Cycles 1-6 for participants with iNHL or MCL. Bendamustine 70 mg/m2 for for participants with CLL only.
Drug: Idelalisib
100 mg or 150 mg administered orally twice daily
Other Names:
  • GS-1101
  • CAL-101
Drug: Rituximab
375 mg/m2 administered intravenously
Other Name: Rituxan
Drug: Bendamustine
90 mg/m2 or 70 mg/m2 administered intravenously
Other Name: Treanda
Experimental: Idelalisib + Bendamustine
Idelalisib 100 mg or 150 mg twice daily plus bendamustine 90 mg/m2 or 70 mg/m2 on Days 1 & 2 of Cycles 1-6.
Drug: Idelalisib
100 mg or 150 mg administered orally twice daily
Other Names:
  • GS-1101
  • CAL-101
Drug: Bendamustine
90 mg/m2 or 70 mg/m2 administered intravenously
Other Name: Treanda
Experimental: Idelalisib + Ofatumumab
Idelalisib 150 mg twice daily plus 12 doses of ofatumumab over the course of 6 months. For participants with CLL only.
Drug: Idelalisib
100 mg or 150 mg administered orally twice daily
Other Names:
  • GS-1101
  • CAL-101
Drug: Ofatumumab
12 doses over 6 months administered intravenously.
Other Name: Arzerra
Experimental: Idelalisib + Fludarabine
Idelalisib 150 mg twice daily plus treatment with oral fludarabine 40 mg/m2 on Days 1-5 of Cycles 1-6. For participants with CLL only.
Drug: Fludarabine
40 mg/m2 administered orally on Days 1-5 of Cycles 1-6
Other Name: Fludara
Experimental: Idelalisib + Everolimus
Idelalisib 150 mg twice daily plus treatment with oral everolimus 10 mg once daily. For participants with MCL only.
Drug: Everolimus
10 mg administered orally twice daily until disease progression
Other Names:
  • Afinitor
  • RAD-001
Experimental: Idelalisib + Bortezomib
Idelalisib 150 mg twice daily plus treatment with Bortezomib administered at a dose of 1.3 mg/m2 as a subcutaneous injection once weekly for 3 weeks (Days 1, 8, and 15) followed by a 13-day rest period. For participants with MCL only.
Drug: Bortezomib
Administered at a dose of of 1.3 mg/m2 as a subcutaneous injection once weekly for 3 weeks (Days 1, 8, and 15) followed by a 13-day rest period.
Other Names:
  • Velcade
  • codenamed PS-341
Experimental: Idelalisib + Chlorambucil
Idelalisib 150 mg twice daily plus treatment with Chlorambucil administered at a dose of 10 mg/m2 on Days 1-7 every 28 days. For participants with CLL only.
Drug: Rituximab
375 mg/m2 administered intravenously
Other Name: Rituxan
Drug: Chlorambucil
Administered at a dose of 10 mg/m2 on Days 1-7 every 28 days to allow appropriate therapy for participants with CLL and to coordinate into a cycle period equivalent to other study treatment regimens.
Other Name: Leukeran
Experimental: Idelalisib + Rituximab + Chlorambucil
Idelalisib 150 mg twice daily + rituximab 375 mg/m2 + chlorambucil 10 mg/m2 for participants with CLL only.
Drug: Chlorambucil
Administered at a dose of 10 mg/m2 on Days 1-7 every 28 days to allow appropriate therapy for participants with CLL and to coordinate into a cycle period equivalent to other study treatment regimens.
Other Name: Leukeran
Experimental: Idelalisib + Lenalidomide + Rituximab
Idelalisib 150 mg twice daily + rituximab 375 mg/m2 + lenalidomide 5, 10 or 20 mg (M.D. Anderson Cancer Center only)
Drug: Idelalisib
100 mg or 150 mg administered orally twice daily
Other Names:
  • GS-1101
  • CAL-101
Drug: Rituximab
375 mg/m2 administered intravenously
Other Name: Rituxan
Drug: Lenalidomide
5, 10, or 20 mg administered orally once daily
Other Name: Revlimid

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age ≥ 18
  • Previously treated with relapsed or refractory disease (refractory defined as not responding to a standard regimen or progressing within 6 months of the last course of a standard regimen)
  • Disease status requirement:

    • For CLL patients, symptomatic disease that mandates treatment as defined by the International Workshop on Chronic Lymphocytic Lymphoma (IWCLL) 2008 criteria
    • For indolent NHL and MCL patients, measurable disease by CT scan defined as at least 1 lesion that measures > 2 cm in a single dimension
  • WHO performance status of ≤ 2
  • For men and women of child-bearing potential, willing to use adequate contraception (ie, latex condom, cervical cap, diaphragm, abstinence, etc.) for the entire duration of the study.

    • For Cohort 7 only: Women of child bearing potential must have 2 negative pregnancy tests prior to starting Lenalidomide.
  • Able to provide written informed consent

Exclusion Criteria

  • Is not a good candidate to receive any of the drugs administered in the study for a given disease (idelalisib, bendamustine, rituximab, ofatumumab, fludarabine, everolimus, bortezomib, or chlorambucil), according to the clinical judgment of the investigator
  • Patients with atypical immunophenotype with t(11:14) translocation or cyclin D1 over‑expression (CLL patients only)
  • Had radiotherapy, radioimmunotherapy, biological therapy, chemotherapy, or treatment with an investigational product within 4-weeks prior to the baseline disease status tests
  • Had treatment with a short course of corticosteroids for symptom relief within 1‑week prior to the baseline disease status tests
  • Has had an allogeneic hematopoietic stem cell transplant
  • Has known active central nervous system involvement of the malignancy
  • Is pregnant or nursing
  • Has active, serious infection requiring systemic therapy. Patients may receive prophylactic antibiotics and antiviral therapy at the discretion of the investigator
  • Has absolute neutrophil count (ANC) < 1000/µL, unless it is related to underlying CLL, MCL or indolent NHL, the latter documented by > 50% infiltration of bone marrow by tumor cells
  • Has platelet count < 75000/µL, unless it is related to underlying CLL, MCL, or iNHL, the latter documented by > 50% infiltration of bone marrow by tumor cells
  • Has serum creatinine ≥ 2.0 mg/dL

    • For Cohort 7 only: Has creatinine clearance < 60 mL/min
  • Has serum bilirubin ≥ 2 mg/dL (unless due to Gilbert's syndrome) for patients with iNHL or CLL; for patients with MCL, serum bilirubin ≥ 1.5 x upper limit of normal
  • Has serum aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≥ 2 x upper limit of normal
  • Has Child-Pugh Class B or C hepatic impairment
  • Has a positive test for HIV antibodies
  • Has active hepatitis B or C (confirmed by RNA test). Patients with serologic evidence of prior exposure are eligible.
  • Prior treatment with idelalisib
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01088048

Locations
United States, Alabama
Clearview Cancer Institute Recruiting
Huntsville, Alabama, United States, 35805
Contact: Kathy Cutter, RN, BSN    256-705-4248    KathyC@ccihsv.com   
Principal Investigator: Marshall T Schreeder, MD         
United States, California
UCLA Recruiting
Los Angeles, California, United States, 90024
Contact: Audrey Rogue-Tayag    310-998-4730    ARTayag@mednet.ucla.edu   
Principal Investigator: Sven De Vos, MD         
Stanford Cancer Center Recruiting
Palo Alto, California, United States, 94304-5548
Contact: Michelle Takahashi    650-736-4032    mtakaha2@stanford.edu   
Principal Investigator: Steven Coutre, MD         
United States, Maryland
Center for Cancer and Blood Disorders Recruiting
Bethesda, Maryland, United States, 20817
Contact: Natalie Bongiorno    301-571-2016    Nbongiorno@ccbdmd.com   
Principal Investigator: Ralph Boccia, MD         
United States, Missouri
Washington University School of Medicine Recruiting
St. Louis, Missouri, United States, 63110
Contact: Kelly Righton    314-747-8084    KRIGHTON@dom.wustl.edu   
Principal Investigator: Nina Wagner-Johnston, MD         
United States, New York
Long Island Jewish Medical Center Recruiting
New Hyde Park, New York, United States, 11040
Contact: Ireen Kahn       IKahn@NSHS.edu   
Principal Investigator: Jacqueline Barrientos, MD         
Weill Medical College of Cornell Recruiting
New York, New York, United States, 10021
Contact: Jenna Fogel    212-746-5269    jef2017@med.cornell.edu   
Principal Investigator: John Leonard, M.D.         
United States, Oregon
Willamette Valley Cancer Institute and Research Center Recruiting
Springfield, Oregon, United States, 97477
Contact: Jeanne Schaffer    541-521-8773    Jeanne.Schaffer@USOncology.com   
Principal Investigator: Jeff Sharman, MD         
United States, Tennessee
Sarah Cannon Research Institute Recruiting
Nashville, Tennessee, United States, 37203
Contact: Ask SARAH    877-MY-1-SCRI (691-7274)    asksarah@scresearch.net   
Principal Investigator: Ian Flinn, MD         
United States, Texas
MD Anderson Cancer Recruiting
Houston, Texas, United States, 77030
Contact: Justin Cumming    713-792-8785    JJCummings@mdanderson.org   
Principal Investigator: Nathan Fowler, MD         
United States, Washington
North Star Lodge Cancer Center Recruiting
Yakima, Washington, United States, 98902
Contact: Beth Parker    509-574-3493    beth.parker@yvmh.org   
Principal Investigator: Thomas Boyd, MD         
Sponsors and Collaborators
Gilead Sciences
Investigators
Study Director: Thomas Jahn, MD Gilead Sciences
  More Information

No publications provided by Gilead Sciences

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Gilead Sciences
ClinicalTrials.gov Identifier: NCT01088048     History of Changes
Other Study ID Numbers: 101-07
Study First Received: March 12, 2010
Last Updated: March 27, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Gilead Sciences:
CLL
non-Hodgkin lymphoma (NHL)
mantle cell lymphoma (MCL)
phosphatidylinositol 3-kinase
bendamustine
CD20 mAb
rituximab
CAL-101
Ofatumumab
indolent non-Hodgkin lymphoma (iNHL)
fludarabine
everolimus
bortezomib
chlorambucil
lenalidomide

Additional relevant MeSH terms:
Leukemia
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Lymphoid
Lymphoma
Lymphoma, Non-Hodgkin
Lymphoma, B-Cell
Lymphoma, Mantle-Cell
Neoplasms by Histologic Type
Neoplasms
Leukemia, B-Cell
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Antibodies, Monoclonal
Immunologic Factors
Fludarabine monophosphate
Everolimus
Sirolimus
Rituximab
Thalidomide
Bendamustine
Fludarabine
Bortezomib
Lenalidomide
Antineoplastic Agents
Chlorambucil
Nitrogen Mustard Compounds
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on April 16, 2014